- Home
- SGA vs IMUX Comparison
SGA vs IMUX Comparison
Compare SGA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- IMUX
- Stock Information
- Founded
- SGA 1986
- IMUX 2016
- Country
- SGA United States
- IMUX United States
- Employees
- SGA N/A
- IMUX N/A
- Industry
- SGA Broadcasting
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- IMUX Health Care
- Exchange
- SGA Nasdaq
- IMUX Nasdaq
- Market Cap
- SGA 74.2M
- IMUX 67.8M
- IPO Year
- SGA 1992
- IMUX N/A
- Fundamental
- Price
- SGA $13.20
- IMUX $0.73
- Analyst Decision
- SGA
- IMUX Strong Buy
- Analyst Count
- SGA 0
- IMUX 6
- Target Price
- SGA N/A
- IMUX $11.60
- AVG Volume (30 Days)
- SGA 17.0K
- IMUX 2.5M
- Earning Date
- SGA 08-07-2025
- IMUX 08-07-2025
- Dividend Yield
- SGA 7.58%
- IMUX N/A
- EPS Growth
- SGA N/A
- IMUX N/A
- EPS
- SGA 0.55
- IMUX N/A
- Revenue
- SGA $111,837,000.00
- IMUX N/A
- Revenue This Year
- SGA N/A
- IMUX N/A
- Revenue Next Year
- SGA $4.84
- IMUX N/A
- P/E Ratio
- SGA $24.17
- IMUX N/A
- Revenue Growth
- SGA N/A
- IMUX N/A
- 52 Week Low
- SGA $10.75
- IMUX $0.56
- 52 Week High
- SGA $16.48
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- SGA 63.76
- IMUX 41.51
- Support Level
- SGA $11.50
- IMUX $0.68
- Resistance Level
- SGA $13.38
- IMUX $0.74
- Average True Range (ATR)
- SGA 0.54
- IMUX 0.06
- MACD
- SGA 0.07
- IMUX 0.00
- Stochastic Oscillator
- SGA 61.37
- IMUX 27.32
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.